Patents Assigned to The Green Cross Corporation
-
Patent number: 5986062Abstract: Human serum albumin obtained by gene manipulation techniques can be purified by a combination of specified steps in which a culture supernatant obtained from a human serum albumin-producing host is subjected to ultrafiltration, heat treatment, acid treatment and another ultrafiltration, followed by subsequent treatments with a cation exchanger, a hydrophobic chromatography carrier and an anion exchanger, and by salting-out to thereby obtain a pure form of human serum albumin which contains substantially no proteinous and polysaccharide contaminants, which is formulated into a pharmaceutical preparation. The thus obtained human serum albumin can further be purified by treating recombinant human serum albumin with a hydrophobic chromatography carrier at pH of 2 to 5 and a salt concentration of 0.4 to 1 and exposing the carrier to a pH of 6 to 8 and a salt concentration of 0.01 to 0.Type: GrantFiled: October 3, 1995Date of Patent: November 16, 1999Assignee: The Green Cross CorporationInventors: Takao Ohmura, Akinori Sumi, Wataru Ohtani, Naoto Furuhata, Kazuya Takeshima, Kaeko Kamide, Munehiro Noda, Masahide Kondo, Syoichi Ishikawa, Kazuhiro Oohara, Kazumasa Yokoyama, Nagatoshi Fujiwara
-
Patent number: 5972367Abstract: Disclosed is an infusion preparation for nutrient supply use. It comprises a sugar, amino acids, electrolytes and a fat emulsion. It has an excellent shelf life without causing precipitation, denaturation and the like in spite of the simultaneous presence of these components. Also disclosed is a container filled with infusion liquids comprising a first and a second compartments separated from each other by a separation means, wherein an infusion liquid containing a fat emulsion and a sugar is included in the first compartment and another infusion liquid containing amino acids and electrolytes is included in the second compartment. Further disclosed are an infusion preparation comprising a fat emulsion and a sugar, and an infusion preparation comprising amino acids and electrolytes.Type: GrantFiled: June 7, 1995Date of Patent: October 26, 1999Assignee: The Green Cross CorporationInventors: Tadaaki Inoue, Hideto Kodaira, Yoshihito Nawa, Ryoichiro Murashima, Shunichi Abe, Kazumasa Yokoyama
-
Patent number: 5948785Abstract: Heterocyclic amide compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.Type: GrantFiled: October 27, 1997Date of Patent: September 7, 1999Assignee: The Green Cross CorporationInventors: Fumihiko Akahoshi, Takuya Yoshimura, Masahiro Eda, Atsuyuki Ashimori, Hajime Fukuyama, Masahide Nakajima, Teruaki Imada, Hideki Okunishi, Mizuo Miyazaki
-
Patent number: 5945103Abstract: The present invention provides a production method of thrombin which can convert prothrombin into thrombin highly efficiently even in the absence of thromboplastin and blood plasma, easily obtain a starting material for use in the conversion of prothrombin into thrombin, and prepare and purify thrombin in an industrial scale. It is characterized in treating a prothrombin-containing aqueous solution with a Ca salt at 0 to 15.degree. C.Type: GrantFiled: May 5, 1997Date of Patent: August 31, 1999Assignee: The Green Cross CorporationInventors: Shinichi Hanada, Yoshinobu Honda, Yasuaki Morisada, Shoichi Miyake, Isahiko Matsumoto
-
Patent number: 5942249Abstract: A composition for oral administration which contains a pyridazinone compound of the formula (I) ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each independently a hydrogen atom or a lower alkyl, X is a halogen atom, a cyano or a hydrogen atom, Y is a halogen atom, a trifluoromethyl or a hydrogen atom, and A is a C.sub.1 -C.sub.8 alkylene optionally substituted by hydroxy, or a pharmacologically acceptable salt thereof, and an organic acid. According to the present invention, a composition for oral administration which is stable to heat, light, moisture and the like and which shows improved dissolution and absorption of a pyridazinone compound can be provided.Type: GrantFiled: January 28, 1998Date of Patent: August 24, 1999Assignees: The Green Cross Corporation, Nissan Chemical Industries, Ltd.Inventors: Toru Iwao, Tomoyo Seki, Nobuo Kondo, Yasuo Ueda
-
Patent number: 5928661Abstract: A controlled release composition comprising a volatile compound such as allyl isothiocyanate and a rosin in a proportion of 0.1 to 100 parts by weight of the compound per 100 parts by weight of the rosin, the controlled release composition further comprising a plasticizer, and the controlled release composition laminated on a substrate or in other forms. The AIT controlled release composition of the present invention can be used for emission of aroma, antimicrobial effect, antibacterial effect, insecticidal action, insectproof effect, fungicidal action, fungiproof action, freshness retention, antiseptic or preservative effect and the like.Type: GrantFiled: May 29, 1997Date of Patent: July 27, 1999Assignees: Rengo Co., Ltd., The Green Cross CorporationInventors: Masao Fujita, Shuji Hirohama, Yoshihiro Hayashi, Shinichi Igarashi, Yuichi Mizukami, Yasushi Sekiyama, Asami Takata
-
Patent number: 5888964Abstract: A method for increasing the placental blood flow, which comprises administering a human-originated antithrombin-III. The human-originated antithrombin-III increases the placental blood flow in mammals and particularly improves intrauterine growth retardation caused by a decreased blood flow. The method is highly safe to the mother and fetus, since it uses human-originated AT-III as an active ingredient, thereby enabling effective and safe treatment of intrauterine growth retardation (IUGR) and the like.Type: GrantFiled: April 24, 1996Date of Patent: March 30, 1999Assignees: The Green Cross Corporation, Hoechst Japan LimitedInventors: Hiroshi Shinyama, Toshiaki Akira, Takeshi Uchida, Masahiro Watanabe
-
Patent number: 5880150Abstract: An antimicrobial agent comprising allyl isothiocyanate (AIT) packaged in a packaging material having a structure wherein part of the pores of a porous packaging substrate is filled with, or said pores are partially or entirely narrowed by a resin impervious to AIT vapor, and a method for controlling the AIT vapor release speed comprising enclosing AIT in the above-mentioned packaging material. According to the present invention, the AIT vapor release speed can be controlled, whereby enabling sustained release of AIT vapor and persistent effect of antimicrobial action. In addition, the antimicrobial agent of the present invention can be widely applied to food industries and various other fields where breeding and reproduction of deleterious microorganisms pose problems, since it is economical, compact and easy to use.Type: GrantFiled: July 10, 1995Date of Patent: March 9, 1999Assignees: The Green Cross Corporation, Rengo Co., Ltd.Inventors: Masao Fujita, Kiyoshi Kamei, Kiyoko Kawazu, Yuichi Mizukami, Yasushi Sekiyama
-
Patent number: 5874404Abstract: Disclosed is an antiallergic composition comprising, as an active ingredient, a peptide which is capable of binding to human IgE, more specifically the high-affinity immunoglobulin E receptor .alpha.-chain or a soluble fragment, which is capable of binding to human IgE, or the high-affinity immunoglobulin E receptor .alpha.-chain. The composition is clinically useful for blocking allergic responses. An animal model for use in the screening of prophylactic and therapeutic compositions for IgE-related diseases is also disclosed.Type: GrantFiled: May 3, 1994Date of Patent: February 23, 1999Assignees: Chisei Ra, The Green Cross CorporationInventors: Chisei Ra, Koji Naito, Minoru Hirama, Ko Okumura, Yukiyoshi Yanagihara
-
Patent number: 5856328Abstract: A circulatory disorder improving agent comprising, as an active ingredient, a dihydropyridine derivative of the formula (I) ##STR1## or an acid addition salt thereof. Said circulatory disorder improving agent is particularly useful as an organ circulation disorder improving agent or peripheral circulation improving agent.Type: GrantFiled: August 20, 1997Date of Patent: January 5, 1999Assignee: The Green Cross CorporationInventors: Hiroshi Shinyama, Toru Kawamura, Minori Okita, Takeshi Uchida, Masahiro Watanabe
-
Patent number: 5856337Abstract: 2-Arylquinolines represented by formula (1): ##STR1## wherein R.sup.1, R.sup.3 to R.sup.9 each represents hydrogen, halogen, lower alkyl, cyclic lower alkyl, aryl, aralkyl, alkoxy or --C.sub.m F.sub.2m+1 ; R.sup.2 represents hydrogen, halogen, lower alkyl, cyclic lower alkyl, aryl, aralkyl, alkoxy, --C.sub.n F.sub.2n+1 or --CH.sub.2 Q, in which Q represents a monovalent organic group obtained by eliminating from an organic compound having --NH-- the hydrogen atom bonded to the nitrogen, or halogen; X represents halogen or hydrogen; Y represents nitro or amino which may be protected with a protecting group; and m and n each represents an integer of from 1 to 6; and processes for producing the 2-arylquinolines.Type: GrantFiled: January 24, 1997Date of Patent: January 5, 1999Assignees: Asahi Glass Co., Ltd., The Green Cross CorporationInventors: Takashi Okazoe, Yoshitomi Morizawa
-
Patent number: 5843773Abstract: A new Bcl-2 related gene "Bfl-1", a polypeptide encoded by said gene, and a plasmid and a transformant comprising said gene are disclosed. The gene can be used to detect cancer.Type: GrantFiled: November 22, 1996Date of Patent: December 1, 1998Assignees: Korea Green Cross Corporation, Postech FoundationInventors: Hee Sup Shin, Young Chul Sung, Seok Il Hong, Sun Sim Choi, Jin Won Yun, Eun Kyoung Choi, In Chul Park
-
Patent number: 5837494Abstract: Disclosed herein is a new E. coli mutant, which is not capable of growing under anaerobic cultivation conditions, said mutant being capable of utilizing glucose as a carbon source but having a suppressed organic acid production under aerobic cultivation conditions. The mutant can advantageously be employed as an expression host system to produce recombinant proteins.Type: GrantFiled: June 30, 1997Date of Patent: November 17, 1998Assignee: Korea Green Cross CorporationInventors: Jong Ho Lee, Han Choi, Il Lae Jung, Doe Sun Na, Young Min Park
-
Patent number: 5817484Abstract: The mutagenized recombinant AT of the present invention wherein some amino acids of the amino acid sequence of a wild-type AT are replaced with another amino acid has an enhanced thermoresistance compared to the wild-type AT, while maintaining its activity. A vector containing a gene encoding the recombinant AT, a microorganism transformed with said vector and a process for producing the recombinant AT with a higher thermoresistance using said microorganism are also disclosed.Type: GrantFiled: November 21, 1995Date of Patent: October 6, 1998Assignees: Korea Institute of Science and Technology, Korea Green Cross CorporationInventors: Myeong-Hee Yu, Ki-Sun Kwon, Kee-Nyung Lee, Hwa-Soo Shin
-
Patent number: 5798357Abstract: An agent for the prophylaxis or treatment of TXA.sub.2 -mediated diseases, particularly, a TXA.sub.2 synthetase inhibitor, which comprises a pyridazinone compound of the formula (I) ##STR1## wherein each symbol is as defined in the specification, or a pharmacologically acceptable salt thereof as an active ingredient. The pyridazinone compound (I) and pharmacologically acceptable salts thereof used in the present invention have prophylactic and therapeutic activities against TXA.sub.2 -mediated diseases, particularly a TXA.sub.2 synthetase inhibitory action and are useful as an agent for the prophylaxis or treatment of TXA.sub.2 -mediated diseases, particularly as TXA.sub.2 synthetase inhibitors.Type: GrantFiled: August 8, 1996Date of Patent: August 25, 1998Assignees: The Green Cross Corporation, Nissan Chemical Industries, Ltd.Inventors: Ruriko Ikegawa, Teruaki Imada, Norifumi Nakamura, Keizo Tanikawa, Nobutomo Tsuruzoe
-
Patent number: 5780634Abstract: Quinolin-2-yl benzoic acid compounds which are useful as intermediates of quinoline compounds having angiotensin II antagonist activity prepared by decarboxylating 2-(carboxyphenyl)-4-quinolinecarboxylic acid compounds in which a carboxyl group bonded to a phenyl group may be esterified, while a carboxyl group bonded to a quinoline ring is not esterified, and both rings may have one or more substituents inert to the decarboxylation reaction.Type: GrantFiled: October 27, 1995Date of Patent: July 14, 1998Assignees: The Green Cross Corporation, Asahi Glass Co., Ltd.Inventors: Yoshihisa Inoue, Hajime Ebisu, Naomichi Ishida, Norifumi Nakamura, Jun Sasaki, Takashi Okazoe, Yoshitomi Morizawa, Arata Yasuda, Shuzhong Wang, Tomoko Ito
-
Patent number: 5770233Abstract: An object of the present invention is to provide an infusion preparation set (a container filled with infusion liquids) useful for preparation of an infusion liquid containing sugars, amino acids, electrolytes, a fat emulsion and vitamins. The present invention is constituted by the use of a container having two compartments which are separated from each other by a separation means, which contains an infusion liquid comprising a fat emulsion, sugars, fat-soluble vitamins and specified water-soluble vitamins in the first compartment and an infusion liquid comprising amino acids, electrolytes and other specified water-soluble vitamins in the second compartment. An infusion preparation containing sugars, amino acids, electrolytes, a fat emulsion and vitamins can be obtained easily and aseptically upon use, by simply removing a separation means and mixing the infusion liquids included in the first and second compartments.Type: GrantFiled: April 21, 1995Date of Patent: June 23, 1998Assignee: The Green Cross CorporationInventors: Takae Kido, Shigeo Ii, Shun-ichi Abe, Kazumasa Yokoyama
-
Patent number: 5770627Abstract: Hydrophobically-modified bioadhesive polyelectrolytes containing a bioadhesive polyelectrolyte and a hydrophobic component are disclosed. Also disclosed are polyelectrolyte-agent compositions wherein the hydrophobically-modified bioadhesive polyelectrolyte is loaded with a pharmaceutically, cosmetically, or prophylactically acceptable agent. Suitable agents have hydrophobic and/or ionic character, and include drugs. The polyelectrolyte-agent compositions may be formulated for administration by topical, oral and/or systemic routes. Methods of administering such agents to an animal are also disclosed, and include administration of an effective amount of the polyelectrolyte-agent composition to the animal.Type: GrantFiled: August 16, 1995Date of Patent: June 23, 1998Assignees: University of Washington, Green Cross CorporationInventors: Tadaaki Inoue, Guohua Chen, Allan S. Hoffman
-
Patent number: 5759819Abstract: A process for producing recombinant human serum albumin (HSA) which comprises culturing an HSA producing host prepared by gene manipulation techniques at a temperature of from 21.degree. to 29.degree. C. Culturing the HSA producing host under such a specified temperature condition makes it possible to increase productivity of HSA production, improve the growth yield of an HSA producing host, and reduce the degree of coloring in the HSA preparation.Type: GrantFiled: November 7, 1996Date of Patent: June 2, 1998Assignee: The Green Cross CorporationInventors: Kaoru Kobayashi, Kenji Tomomitsu, Shinobu Kuwae, Tomoshi Ohya, Toyoo Ohda
-
Patent number: 5756313Abstract: A plasmid for a yeast host, the plasmid comprising in sequence: (1) a yeast derived promoter, (2) an albumin-encoding region placed under control of the yeast-derived promoter, (3) a transcription terminator and (4) a sequence homologous to a part of the yeast host chromosomal sequence such that the plasmid is capable of being integrated into the yeast host cell chromosome and wherein the plasmid is incapable of autonomous replication in yeast cells; a yeast host transformed with the above plasmid; a method of producing a yeast transformant which comprises transforming a yeast host by integrating at least two different plasmids each having a sequence homologous to a part of the host yeast chromosomal sequence one at a time into the chromosome of the yeast host cell; and a method of producing albumin which comprises cultivating the above transformant and recovering the thus-produced albumin.Type: GrantFiled: October 20, 1993Date of Patent: May 26, 1998Assignee: The Green Cross CorporationInventors: Ken Okabayashi, Hideyuki Oi, Kazumoto Hirabayashi, Masami Miura, Miho Shimizu, Haruhide Kawabe